vs
PROG Holdings, Inc.（PRG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是PROG Holdings, Inc.的1.2倍（$772.1M vs $651.6M），Revvity净利率更高（12.7% vs 5.5%，领先7.2%），PROG Holdings, Inc.同比增速更快（457.1% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 4.9%）
PROG Holdings是一家总部位于美国的金融科技企业，主要面向美国本土市场提供灵活的租购及销售点融资解决方案，核心业务涵盖零售合作伙伴融资、消费信贷与支付服务，帮助消费者无需满足传统信用要求即可购买电子产品、家居用品等商品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PRG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$651.6M
营收增速更快
PRG
高出451.3%
5.9%
净利率更高
RVTY
高出7.2%
5.5%
两年增速更快
RVTY
近两年复合增速
4.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $651.6M | $772.1M |
| 净利润 | $36.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.0% | 14.5% |
| 净利率 | 5.5% | 12.7% |
| 营收同比 | 457.1% | 5.9% |
| 净利润同比 | 3.8% | 3.9% |
| 每股收益（稀释后） | $3.68 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGRVTY
| Q1 26 | $651.6M | — | ||
| Q4 25 | $525.4M | $772.1M | ||
| Q3 25 | $595.1M | $698.9M | ||
| Q2 25 | $604.7M | $720.3M | ||
| Q1 25 | $684.1M | $664.8M | ||
| Q4 24 | $558.9M | $729.4M | ||
| Q3 24 | $606.1M | $684.0M | ||
| Q2 24 | $592.2M | $691.7M |
净利润PRGRVTY
| Q1 26 | $36.1M | — | ||
| Q4 25 | $40.5M | $98.4M | ||
| Q3 25 | $33.1M | $46.7M | ||
| Q2 25 | $38.5M | $53.9M | ||
| Q1 25 | $34.7M | $42.2M | ||
| Q4 24 | $57.5M | $94.6M | ||
| Q3 24 | $84.0M | $94.4M | ||
| Q2 24 | $33.8M | $55.4M |
毛利率PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率PRGRVTY
| Q1 26 | 10.0% | — | ||
| Q4 25 | 6.9% | 14.5% | ||
| Q3 25 | 9.0% | 11.7% | ||
| Q2 25 | 10.0% | 12.6% | ||
| Q1 25 | 8.2% | 10.9% | ||
| Q4 24 | 8.9% | 16.3% | ||
| Q3 24 | 8.1% | 14.3% | ||
| Q2 24 | 9.4% | 12.4% |
净利率PRGRVTY
| Q1 26 | 5.5% | — | ||
| Q4 25 | 7.7% | 12.7% | ||
| Q3 25 | 5.6% | 6.7% | ||
| Q2 25 | 6.4% | 7.5% | ||
| Q1 25 | 5.1% | 6.4% | ||
| Q4 24 | 10.3% | 13.0% | ||
| Q3 24 | 13.9% | 13.8% | ||
| Q2 24 | 5.7% | 8.0% |
每股收益（稀释后）PRGRVTY
| Q1 26 | $3.68 | — | ||
| Q4 25 | $0.99 | $0.86 | ||
| Q3 25 | $0.82 | $0.40 | ||
| Q2 25 | $0.95 | $0.46 | ||
| Q1 25 | $0.83 | $0.35 | ||
| Q4 24 | $1.33 | $0.77 | ||
| Q3 24 | $1.94 | $0.77 | ||
| Q2 24 | $0.77 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $69.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $774.4M | $7.3B |
| 总资产 | $2.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGRVTY
| Q1 26 | $69.4M | — | ||
| Q4 25 | $308.8M | $919.9M | ||
| Q3 25 | $292.6M | $931.4M | ||
| Q2 25 | $222.0M | $991.8M | ||
| Q1 25 | $213.3M | $1.1B | ||
| Q4 24 | $90.9M | $1.2B | ||
| Q3 24 | $221.7M | $1.2B | ||
| Q2 24 | $250.1M | $2.0B |
总债务PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $594.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $643.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PRGRVTY
| Q1 26 | $774.4M | — | ||
| Q4 25 | $746.4M | $7.3B | ||
| Q3 25 | $703.6M | $7.4B | ||
| Q2 25 | $668.7M | $7.6B | ||
| Q1 25 | $654.4M | $7.6B | ||
| Q4 24 | $650.3M | $7.7B | ||
| Q3 24 | $630.8M | $7.9B | ||
| Q2 24 | $581.9M | $7.9B |
总资产PRGRVTY
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.6B | $12.2B | ||
| Q3 25 | $1.5B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.5B | $12.4B | ||
| Q4 24 | $1.5B | $12.4B | ||
| Q3 24 | $1.4B | $12.8B | ||
| Q2 24 | $1.5B | $13.4B |
负债/权益比PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.99× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-54.9M | $182.0M | ||
| Q3 25 | $110.0M | $138.5M | ||
| Q2 25 | $69.9M | $134.3M | ||
| Q1 25 | $209.9M | $128.2M | ||
| Q4 24 | $-84.5M | $174.2M | ||
| Q3 24 | $31.9M | $147.9M | ||
| Q2 24 | $55.4M | $158.6M |
自由现金流PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-57.5M | $161.8M | ||
| Q3 25 | $106.5M | $120.0M | ||
| Q2 25 | $68.0M | $115.5M | ||
| Q1 25 | $208.0M | $112.2M | ||
| Q4 24 | $-86.8M | $149.8M | ||
| Q3 24 | $29.8M | $125.6M | ||
| Q2 24 | $53.5M | $136.6M |
自由现金流率PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | -10.9% | 21.0% | ||
| Q3 25 | 17.9% | 17.2% | ||
| Q2 25 | 11.2% | 16.0% | ||
| Q1 25 | 30.4% | 16.9% | ||
| Q4 24 | -15.5% | 20.5% | ||
| Q3 24 | 4.9% | 18.4% | ||
| Q2 24 | 9.0% | 19.7% |
资本支出强度PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.3% | 2.4% | ||
| Q4 24 | 0.4% | 3.4% | ||
| Q3 24 | 0.3% | 3.3% | ||
| Q2 24 | 0.3% | 3.2% |
现金转化率PRGRVTY
| Q1 26 | — | — | ||
| Q4 25 | -1.36× | 1.85× | ||
| Q3 25 | 3.32× | 2.97× | ||
| Q2 25 | 1.82× | 2.49× | ||
| Q1 25 | 6.05× | 3.03× | ||
| Q4 24 | -1.47× | 1.84× | ||
| Q3 24 | 0.38× | 1.57× | ||
| Q2 24 | 1.64× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRG
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
